uniQure’s (QURE) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of uniQure (NASDAQ:QURE) in a research report report published on Thursday,Benzinga reports. Chardan Capital currently has a $53.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on the company. Mizuho boosted their price target on uniQure from $30.00 to $60.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. Cantor Fitzgerald lifted their price objective on uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. Benchmark reissued a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Sunday, November 30th. Finally, Royal Bank Of Canada dropped their price target on uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a research note on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $64.42.

uniQure Trading Down 6.2%

Shares of uniQure stock opened at $21.33 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The firm has a 50-day moving average of $44.57 and a 200-day moving average of $26.17. uniQure has a 52-week low of $6.62 and a 52-week high of $71.50. The stock has a market cap of $1.33 billion, a PE ratio of -4.86 and a beta of 0.59.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. As a group, sell-side analysts forecast that uniQure will post -3.75 EPS for the current year.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the transaction, the chief executive officer owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 314,560 shares of company stock worth $12,362,568. Insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vestal Point Capital LP boosted its holdings in shares of uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after acquiring an additional 1,767,572 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of uniQure by 22.6% during the third quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after purchasing an additional 819,444 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of uniQure by 6.9% during the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after purchasing an additional 101,598 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in shares of uniQure in the second quarter valued at approximately $29,217,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.